Synapse - Alison Schram

Search Within

Alison Michele Schram

Results (122)

Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial

Journal Article

Schram, A. M.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, T. M.; Jin, N.; Ulahannan, S. V.; more...
JAMA Oncology (2023)

Fulltext@MSK | Save

PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations

Meeting Abstract

Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Meeting Abstract

Park, J. O.; Meng, D. T. W.; Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Cassier, P.; Kamath, S. D.; Dotan, E.; Kim, R.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Meeting Abstract

Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

Meeting Abstract

Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma

Meeting Abstract

Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development

Meeting Abstract

Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mechanisms of acquired resistance to TRK inhibitors

Meeting Abstract

Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)

Meeting Abstract

Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

Meeting Abstract

Dumbrava, E. E.; Johnson, M. L.; Tolcher, A. W.; Shapiro, G.; Thompson, J. A.; El-Khoueiry, A. B.; Vandross, A. L.; Kummar, S.; Parikh, A. R.; Munster, P. N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save